A global gene expression profiling specific to the early process of tumor promotion by fenbendazole (FB) or phenobarbital (PB) in a rat two-stage hepatocarcinogenesis model revealed 33 genes to show altered expression in common with both chemicals. The immunohistochemical distribution of transferrin receptor (Tfrc), nuclear receptor subfamily 0, group B, member 2 (Nr0b2) and minichromosome maintenance deficient 6 (MCM6), included in the altered expression profile, were therefore examined in FB-and PB-induced proliferative lesions at both early and late stages of tumor promotion. In addition, immunoexpression of transforming growth factor b receptor (TGFbR) I, TGFbRII, phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and phosphorylated phosphatase and tensin homolog deleted on chromosome 10 (pPTEN) was also examined. In the early stage, most hepatocellular foci positive for glutathione S-transferase placental form (GST-P) showed co-expression of TGFbRI and lack of PTEN and pPTEN, some GST-P-positive foci co-expressing Tfrc and Nr0b2. In the late stage, selective expression of TGFbRI, but not TGFbRII, was also observed in many adenomas and carcinomas consistently expressing GST-P. Nr0b2 was variably expressed in the proliferative lesions, irrespective of the carcinogenic stage. Like the GST-P-positive foci, adenomas and carcinomas consistently lacked PTEN and pPTEN. Expression of Tfrc and MCM6 was increased in parallel with the carcinogenic stage. In conclusion, loss of PTEN and dysregulation of transforming growth factor b signaling can be considered to be involved in rat hepatocarcinogenesis from early stages. Selective expression of Tfrc in proliferative lesions suggests an involvement of changes in iron homeostasis during the process of tumor promotion/progression driven by FB or PB.
Introduction
Molecular events in multistep carcinogenesis due to non-genotoxic carcinogens remain largely unclear. Currently, although acceptable daily intake levels have been established for non-genotoxic carcinogens such as food additives, pesticides and animal drugs contained in food, a more thorough understanding of the mechanisms of nongenotoxic carcinogenesis is needed to secure human health. The carcinogens in question usually exert tumor-promoting activity of target organs in two-stage carcinogenesis models in rodents, and signatures of carcinogenic responses can be determined by analysis of preneoplastic lesions generated at early stages of tumor promotion. This is the rationale for global gene expression profiling focusing on early stages of carcinogenesis for elucidation of putative molecular mechanisms responsible for early carcinogenic actions.
The glutathione S-transferase placental form (GST-P) has been identified as a reliable marker for preneoplastic lesions as end points in rat liver for rapid detection of carcinogenic agents (1) . However, it is known that only a small proportion of such foci actually progress to liver tumors. In a recent report, it is suggested that double-positive foci for GST-P and transforming growth factor (TGF) a in the early stages of rat hepatocarcinogenesis may be most probably to develop into tumors with promotion (2) . Also, dysregulation of TGFb signaling, such as altered expression of transforming growth factor b receptors (TGFbRs), has been considered to play a critical role in the promotion and progression stages of hepatocarcinogenesis, both in humans and rodents (3) (4) (5) . It has been reported that expression of TGFb and its receptors is altered in preneoplastic lesions in rat liver during the tumor promotion stage (6, 7) . Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor gene involved in a variety of tumor types, and down-regulation of PTEN expression may contribute to the development of human hepatocellular carcinomas (8, 9) . In rats, clear roles of PTEN in hepatocarcinogenesis remain to be explored (10) .
In the present study, to determine molecular mechanisms involved in the non-genotoxic hepatocarcinogenesis in rat liver, we performed a global expression profiling of mRNAs specific to the early stage of tumor promotion by fenbendazole (FB), an anti-helminthic drug (11) , and phenobarbital (PB), a well-studied hepatocarcinogenesis promoter (12) , in a rat two-stage hepatocarcinogenesis model using a medium-term liver bioassay (13, 14) . Reduction of connexin 32 in centrilobular hepatocytes as well as cytochrome P450 (CYP) 1A2 induction have been suggested to be involved in the mechanism of liver tumor promotion by FB (11) . PB is also known to induce CYP enzymes, particularly CYP2B1/2 and CYP3A2 (15) . It has been reported that PB inhibits cell-to-cell communication, stimulates proliferation and inhibits apoptosis of hepatocytes in preneoplastic foci (16) . In addition, increased oxidative stresses due to activation of detoxifying enzymes are suggested to be responsible for hepatocarcinogenesis by PB (15) . Based on the expression profiles obtained in the present study, we further examined cellular localization of molecules that showed altered expression at the early stage of hepatocarcinogenesis by FB and PB in common, such as transferrin receptor (Tfrc), nuclear receptor subfamily 0, group B, member 2 (Nr0b2) and minichromosome maintenance deficient 6 (MCM6), immunohistochemically in the FB-or PB-induced hepatocellular adenomas and carcinomas as well as in the liver cell foci. We also additionally examined changes in immunolocalization of TGFbRs, PTEN and phosphorylated phosphatase and tensin homolog deleted on chromosome 10 (pPTEN) during the course of hepatocarcinogenesis.
Materials and methods
Chemicals FB (CAS No. 43210-67-9) was purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan). PB sodium (CAS No. 57-30-7) was obtained from Wako Pure Chemicals Industries (Osaka, Japan) and N-diethylnitrosamine (DEN, CAS No. 55-18-5) from Tokyo Chemical Industry, Ltd (Tokyo, Japan).
Animal experiments
Male 5-week-old F344/DuCrj rats were purchased from Charles River Japan (Kanagawa, Japan) and acclimatized on powdered basal diet (CRF-1; Oriental Yeast, Tokyo, Japan) and tap water ad libitum for 1 week. They were housed in Abbreviations: CYP, cytochrome P450; DEN, N-diethylnitrosamine; FB, fenbendazole; GST-P, glutathione S-transferase placental form; MCM6, minichromosome maintenance deficient 6; Nr0b2, nuclear receptor subfamily 0, group B, member 2; PH, partial hepatectomy; PB, phenobarbital; PTEN, phosphatase and tensin homolog deleted on chromosome 10; pPTEN, phosphorylated phosphatase and tensin homolog deleted on chromosome 10; RT, reverse transcription; PCR, polymerase chain reaction; Tfrc, transferrin receptor; TGF, transforming growth factor; TGFbR, transforming growth factor b receptor.
Ó The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org 2218 polycarbonate cages with sterilized softwood chips as bedding in a barriermaintained animal room conditioned at 23-25°C and 50-60% humidity on a 12-h light/dark cycle.
In the experiment 1, for gene expression profiling and immunohistochemical examination of rat livers at the early stage of tumor promotion, a two-stage hepatocarcinogenesis model was employed using a medium-term liver bioassay (13, 14) . A total of 120 rats were divided into 10 groups. Seven groups were initiated with a single intraperitoneal injection of DEN (200 mg/kg, dissolved in saline) and the others received a single intraperitoneal injection of saline vehicle alone. Two weeks later, rats in the DEN-initiated groups were fed diet containing FB 400, 1200 or 3600 p.p.m. (DEN þ FB groups) or PB 56, 167 or 500 p.p.m. (DEN þ PB groups) or basal diet (DEN-alone group). The rats without initiation were given FB 3600 p.p.m. (FB group) or PB 500 p.p.m. (PB group) or basal diet (untreated control group). The highest doses of FB or PB were set as concentrations that exhibited tumor promotion effects in rat liver in previous reports (FB, 11; PB, 12). The animals were subjected to twothirds partial hepatectomy (PH) at week 3 except for sham surgery in the untreated control group. At week 8, the animals were killed under deep ether anesthesia by exsanguination, and their livers were immediately removed and weighed. The liver tissues were immersed in RNAlaterÒ solution (Ambion, Austin, TX) at 4°C overnight and then stored at À80°C until use after removing the solution. In addition, liver slices were fixed in 10% phosphate-buffered formalin (pH 7.4) and processed routinely for histopathological examination.
In experiment 2, to investigate immunohistochemical distribution of selected proteins in late stages of tumor promotion, 35 animals each initiated with DEN were given diet containing FB 3600 p.p.m. or PB 500 p.p.m. from 2 weeks after initiation. They were subjected to PH at week 3 and maintained until week 59 to induce hepatocellular tumors. The livers of surviving animals were removed and the liver slices containing neoplastic lesions grossly (1 slice per a rat) were fixed in 10% phosphate-buffered formalin and prepared for histopathological examination.
The treatment groups in experiments 1 and 2 are summarized in supplementary Table S1 (available at Carcinogenesis and Online). The animal protocol was reviewed and approved by the Animal Care and Use Committee of the National Institute of Health Sciences, Japan.
RNA preparation
For microarray analysis and subsequent real-time reverse transcription (RT)-polymerase chain reaction (PCR) analysis, total RNA was isolated from livers of four rats in each group in experiment 1 using an RNeasy Mini Kit (QIAGEN K.K., Tokyo, Japan). Concentrations and quality of RNA were determined with a RiboGreen RNA Quantitation Kit (Molecular Probes, Eugene, OR) and an RNA 6000 Nano LabChip Kit (Agilent Technologies Japan, Ltd, Tokyo, Japan), respectively.
Microarray analysis
Five microgram aliquots of total RNA were subjected to amplification, consisting of RT and subsequent in vitro one-step transcription, using a MessageAmp TM II aRNA amplification Kit (Ambion) with a T7 oligo (dT) primer, according to the manufacturer's protocol. During the in vitro transcription, generated aRNAs were labeled with biotin-16-UTP and biotin-11-CTP (Enzo Biochem, Farmingdale, NY). Aliquots of 20 lg of biotinylated aRNA were fragmented, hybridized with a GeneChipÒ Rat Genome 230 2.0 Array (Affymetrix, Santa Clara, CA) at 45°C for 18 h, stained with streptavidin-R-phycoerythrin conjugates (Molecular Probes) and then scanned with a GeneChipÒ Scanner 3000 (Affymetrix).
Selection of genes and normalization of expression data were performed using GeneSpringÒ software (version 7.2; Silicon Genetics, Redwood City, CA). To normalize chip-wide variation in intensity, per chip normalization was performed by dividing the signal strength for each gene with the level of the 50th percentile of the measurement in the chip, and each gene was divided by the average intensity in the samples of untreated control or DEN-alone groups.
Genes showing expression change with differences at least 2-fold in magnitude from the untreated control or DEN-alone groups, as well as the 'presence' signal in . expression changes in the PB-and DEN-alone groups from that showing expression changes in the DEN þ PB 500 p.p.m. Genes showing altered expression in common with both chemicals were also selected. Among genes selected at the highest dose of each carcinogen, those showing dose-related expression changes were further identified by analysis of expression levels with the low-and middle-dose groups for each chemical.
Real-time RT-PCR
Quantitative real-time RT-PCR was performed for confirmation of expression values obtained with microarrays using an ABI Prism 7900HT (Applied Biosystems Japan Ltd, Tokyo, Japan). The following genes were selected as targets: alcohol dehydrogenase 1 (Adh1), syntaxin 6 (Stx6), pregnancy-induced growth inhibitor (Okl38), v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (Mafb), Nr0b2, dual specificity phosphatase 1 (Dusp1), Axin2 and Igfbp1. One microgram of total RNA was applied to RT with a High-Capacity cDNA Archive Kit (Applied Biosystems Japan Ltd) in a 100-ll total reaction volume. For real-time PCR analysis, ABI Assays-onDemand TM TaqMan probe and primer sets from Applied Biosystems (available at https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=cat Navigate2&catID=601267/) were used except for Adh1. Real-time PCR was performed in a 50-ll reaction volume using the TaqMan probe detection system (Applied Biosystems Japan Ltd) with specific primers, the corresponding TaqManÒ MGB probes (FAM TM dye labeled) and RT products. For Adh1, the primer sets were designed using Primer ExpressÒ software (version 2.0; Applied Biosystems Japan Ltd), and the sequences were TTG AAG GAA ACA ACT CCA TAT TCA TT (forward) and CAT GGC CGC TCT GCT TCT A (reverse). Amplified transcript levels were measured with the SYBR Green detection system in a 50-ll reaction mixture containing SYBRÒ Green PCR Master Mix (Applied Biosystems Japan Ltd), target primers and RT products. For quantification of expression data, a standard curve method was applied. Expression values were normalized to two housekeeping genes, glyceraldehyde 3-phosphate dehydrogenase and hypoxanthine-guanine phosphoribosyltransferase.
Immunohistochemistry Formalin-fixed, paraffin-embedded liver sections were subjected to immunohistochemistry utilizing a VECTASTAINÒ Elite ABC Kit (Vector Laboratories, Burlingame, CA) with 3,3#-diaminobenzidine/H 2 O 2 as the chromogen. Rabbit polyclonal antibodies against GST-P (MBL, Nagoya, Japan; Catalog No. 311, 1:1000) were applied for all liver sections obtained at both 6 and 57 weeks of tumor promotion. Serial sections of eight rats of the untreated control, DEN-alone, DEN þ FB 3600 p.p.m. and DEN þ PB 500 p.p.m. groups at week 6 of promotion as well as all the hepatocellular tumors generated after promotion with FB or PB were subjected to immunohistochemistry for Tfrc For antigen retrieval, the sections were heated in 10 mM citrate buffer by autoclaving for 10 min before incubation with the TGFbRI and MCM6 antibodies or for 20 min before incubation for PTEN and pPTEN. In the Nr0b2, Trfc and TGFbRII cases, sections were heated by microwave for 10 min before incubation.
Analysis of immunolocalization
The numbers and areas of GST-P-positive foci and the total areas of livers at week 6 of tumor promotion were measured using an Image Processor for Analytical Pathology (IPAP-WIN; Sumika Technoservice, Osaka, Japan), and then the values per unit area (cm 2 ) of liver section were calculated. Cellular localization of immunohistochemically stained molecules was evaluated in relation with GST-P-positive foci and neoplastic lesions using serial sections without applying double-labeling experiments with GST-P. For evaluation of the immunoreactivity of Tfrc and Nr0b2 in liver cells outside GST-P-positive foci at 6 weeks of promotion, staining intensity was scored as 0 (none), 1 (slight), 2 (moderate) and 3 (strong) by observation of five randomly selected areas/rat at 200-fold magnification. For evaluation of the expression of TGFbRI, TGFbRII, PTEN, pPTEN, Tfrc and Nr0b2 in proliferative lesions (GST-P-positive foci at both 6 and 57 weeks; hepatocellular adenomas and carcinomas at 57 weeks), immunoreactivity was classified as increased, unchanged or decreased as compared with the expression levels of surrounding Molecules in hepatocarcinogenesis liver cells. Numbers of MCM6-positive cells and total number of liver cells were counted by observation of five randomly selected areas/rat at 200-fold magnification at week 6 and counted in individual GST-P-positive foci, adenomas and carcinomas at 57 weeks, and then, MCM6-positive cell index was calculated.
Statistical analysis
Data for the numbers and areas of GST-P-positive foci were assessed by oneway analysis of variance or the Kruskal-Wallis test following Bartlett's test. When statistically significant differences were indicated, the Dunnett's multiple test was employed for comparison with the DEN-alone group. The data for gene expression levels from real-time RT-PCR analysis and MCM6-positive cell indices were analyzed by the Student's or Welch's t-test following a test for equal variance. For grading immunohistochemical findings, scores of Tfrc and Nr0b2 were analyzed with the Mann-Whitney's U-test between the DEN-alone group and DEN þ FB or DEN þ PB groups. For the microarray data, statistical analysis was performed with GeneSpringÒ software, and the significance of gene expression changes was analyzed by the Student's t-test or analysis of variance between the DEN-alone and DEN þ FB or DEN þ PB groups.
Results

Microarray analysis
In all, 33 genes (15 genes up-regulated and 18 genes down-regulated) were identified as showing altered expression at week 6 of tumor promotion by both FB and PB (Table I) . Examples showing doserelated expression changes numbered 18 and 32 in the DEN þ FB and DEN þ PB groups, respectively (supplementary Tables S2 and S3 are available at Carcinogenesis and Online). Among these, there were several whose products are involved in suppression of cell proliferation, such as Okl38 (17), protein arginine N-methyltransferase 5 (Prmt5_predicted) (18) and Dusp1 (19) . In both DEN þ FB and DEN þ PB groups, up-regulation of Okl38 and down-regulation of Dusp1 and Mafb, were observed dose relatedly. Particularly, Mafb showed down-regulation from the lowest dose of both chemicals. The results of real-time RT-PCR for validation of microarray data are summarized in Table II . Expression levels at the highest dose of promotion in each chemical were compared between the microarray and real-time RT-PCR values. In both FB-and PB-promoted liver, many expression changes were similar between the two analysis systems, except for changes of Stx6. In addition, a low magnitude of alteration was found for Adh1 by real-time RT-PCR in the PBpromoted liver.
Since up-regulation of MCM6, which is involved in DNA replication and reported as a marker of proliferating cells (20) , was found in the DEN þ FB 3600 p.p.m. group, we selected MCM6 for immunohistochemical analysis to detect cell proliferation activity. Among genes showing altered expression specific to the early stages of tumor promotion by both FB and PB, up-regulation of Tfrc and downregulation of Nr0b2 were observed with dose relation in the decrease of Nr0b2 by FB (Table I; supplementary Table S2 is available at Carcinogenesis Online). Tfrc is a receptor for transferrin, which plays a major role in intracellular uptake of iron (21) . It has been reported that expression of Tfrc and iron homeostasis are altered in preneoplastic nodules and hepatocellular tumors in rats (22, 23) . Nr0b2 is an atypical orphan nuclear receptor that lacks a conventional DNAbinding domain, which acts as a co-regulator of various nuclear receptors and negatively regulates the gene expression of glucose 6-phosphatase (G6Pase), CYP7A1 and PEPCK (24, 25) . In the preneoplastic foci in rat liver, it is well known that loss of G6Pase is commonly observed (26) . Thus, we also selected Tfrc and Nr0b2 for immunolocalization analysis in hepatocellular preneoplastic foci and tumors.
Immunolocalization at the early stage of tumor promotion At week 6 of tumor promotion, the foci induced by FB or PB were predominantly of eosinophilic type and positive for GST-P (supplementary Table S4 is available at Carcinogenesis and Online). The numbers and areas of GST-P-positive foci were significantly increased in the DEN þ FB 1200 and 3600 p. Table S5 is available at Carcinogenesis Online). In the untreated controls, FB-alone and PB-alone groups, very few GST-P-positive foci were observed, and there were no intergroup differences in numbers and areas. Tfrc showed diffuse liver cell immunoreactivity in the untreated controls and DEN-alone groups, and increased intensity was observed in liver cells on promotion with FB or PB, in parallel with the microarray results ( Figure 1A ; supplementary Table S4 is available at Carcinogenesis Online). In addition, a small population of GST-Ppositive foci exhibited strong immunoreactivity for Tfrc.
Nr0b2-positive liver cells were found diffusely in the untreated control group. Decreased numbers of Nr0b2-positive cells were observed in the DEN þ FB 3600 p.p.m. and DEN þ PB 500 p.p.m. groups, in parallel with the microarray data ( Figure 1B ; supplementary  Table S4 is available at Carcinogenesis and Online). However, some liver cell foci positive for GST-P paradoxically showed increased numbers of Nr0b2-positive cells as compared with surrounding liver cells.
MCM6-positive cells were detected mainly in regenerative nodules including oval cells in the DEN þ FB 3600 p.p.m. group, and their numbers were significantly increased in this group as compared with the DEN-alone group ( Figure 1C ).
TGFbRI and TGFbRII were immunolocalized in normal liver cells diffusely but weakly in all groups, including untreated controls (supplementary Table S4 is available at Carcinogenesis Online). Many GST-P-positive foci showed intense immunoreactivity for TGFbRI, especially in the DEN þ FB 3600 p.p.m. group (Figure 2A ). In contrast, very small populations of foci showed increased or decreased immunoreactivity for TGFbRII. PTEN and pPTEN immunoreactivity was diffusely but weakly observed in normal liver cells in all groups, including untreated controls. It was generally lacking in foci ( Figure  2A ; supplementary Table S4 is available at Carcinogenesis Online). On co-localization analysis of each molecule in association with GST-P positivity using serial sections, increased immunoreactivity of TGFbRI and decreased immunoreactivity of PTEN and pPTEN were found in most GST-P-positive foci compared with surrounding liver cells in the DEN þ FB 3600 p.p.m. group. Some foci also showed coexpression of Tfrc and Nr0b2 ( Figure 2B ). In the DEN þ PB group, although similar immunolocalization changes to FB group were observed for these molecules, rates of foci showing altered immunoreactivity were lower than those in the DEN þ FB group.
Immunolocalization at the late stage of tumor promotion Many adenomas and carcinomas were obtained after promotion by FB or PB for 57 weeks. Most adenomas exhibited eosinophilic cytoplasm and solid growth, and carcinomas frequently showed trabecular and solid growth patterns. Foci observed at the late stage were mostly eosinophilic, but basophilic and clear cell types were also found. There were no major differences between the incidence and histological types of proliferative lesions induced by FB or PB.
All adenomas and carcinomas were positive for GST-P, although a small subset of foci, such as the basophilic type, appeared negative ( Figure 3 ; supplementary Table S4 is available at Carcinogenesis Online). The immunoreactivity of TGFbRI was increased in the proliferative lesions in comparison with surrounding liver cells, and the percentages of lesions strongly expressing TGFbRI were increased in adenomas and carcinomas, in both FB and PB groups. Localized expression of TGFbRII in proliferative lesions was largely lacking, although a small proportion of lesions showed increased or decreased immunoreactivity. Nr0b2 was variably positive in the proliferative lesions, without relation to development from foci to carcinomas. PTEN and pPTEN were weakly positive in the liver cells outside the proliferative lesions, but were consistently lacking in FB-and PBinduced foci, adenomas and carcinomas. Immunoreactivity of Tfrc and MCM6 increased in parallel with the stage of lesion development. 
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MCM6-positive cell indices did not differ in relation with the immunoreactive patterns of TGFbRI or TGFbRII in each type of proliferative lesion in either DEN þ FB or DEN þ PB group, although carcinomas showed particular variability (Figure 4 ). Foci and adenomas showing different expression patterns of Nr0b2 did not show obvious variation in the MCM6-positive cell index. On the other hand, carcinomas showing decreased immunoreactivity of Nr0b2 exhibited higher MCM6-positive cell indices as compared with those showing unchanged expression of this molecule as compared with surrounding liver cells in the DEN þ PB group. Although statistically non-significant, a similar tendency was also observed in the DEN þ FB group. In both DEN þ FB and DEN þ PB groups, MCM6-positive cell indices in adenomas or carcinomas lacking PTEN and pPTEN immunoreactivity were lower than in the corresponding lesions showing unchanged expression of these antigens as compared with surrounding liver cells (DEN þ PB group: significantly different for pPTEN in adenomas; DEN þ FB group: significantly different for PTEN and pPTEN in carcinomas). There was an increasing tendency for MCM6-positive cell indices in adenomas and carcinomas that showed increased immunoreactivity of Tfrc as compared with those in the corresponding lesions showing unchanged expression in both DEN þ FB and DEN þ PB groups, but it was statistically non-significant.
Discussion
Both FB and PB are known to induce CYPs, and it has been suggested that effects such as inhibition of cell-to-cell communication and oxidative stress are involved in their mechanisms of carcinogenic action (11, 15, 16) . In the present study, we subtracted gene clusters simply responding to FB and PB alone as well as those responding to initiation and PH from those showing altered expression after initiation plus PH and following promoter treatment, and therefore, the obtained genes can be considered to play some role in the promotion process by non-genotoxic hepatocarcinogens. As a result, chemically inducible genes related to drug detoxification, inhibition of cell-to-cell communication and oxidative stress responses were excluded from the expression profile. Several genes, such as Okl38, Prmt5 and Dusp1, are known to be related to suppression of cell proliferation (17) (18) (19) , suggesting that expression changes of genes toward growth suppression observed in the early stages of tumor promotion was probably a reflection of gene expression in mitotically inactive uninitiated cells that comprise the predominant cell population in the liver at this time point.
Immunohistochemical examination revealed that a subset of GST-P-positive foci exhibit increased immunolocalization of Tfrc, Nr0b2 and TGFbRI and decreased immunoexpression of PTEN and pPTEN after promotion by FB or PB. In contrast to the promotion with FB, only a small proportion of foci showed altered expression by PB at the same early stage. This difference between FB and PB might reflect differences in the action or potential for promotion of these chemicals. However, since similar immunoexpression patterns were observed in the FB-and PB-induced tumors at the late stage, it is presumed that the role of the molecules examined here may be similar in the process of hepatocarcinogenesis. Simply, slower growth of GST-P-positive foci in the PB-promoted livers as compared with the FB-promoted ones might have lowered the chance of acquiring or losing phenotypes within the foci. It should be noted that the size of foci with PB was rather small as compared with the FB case.
Increased expression of Tfrc was observed here in a subset of GST-P-positive foci in the early stage of tumor promotion by FB or PB, and levels increased in proportion to the stage of lesion development. Iron plays an important role in many essential cell functions including the synthesis of enzymes necessary for cellular growth and metabolism, and expression of Tfrc is closely linked to the proliferation status of the cell (27) . It has been reported that expression of Tfrc and iron homeostasis is altered in preneoplastic nodules and hepatocellular tumors in rats (22, 23) . A correlation between Tfrc expression and cell proliferation has been also shown in human breast carcinomas (28) . Therefore, it is suggested that change in iron homeostasis was linked to the processes of tumor promotion and progression by FB and PB in the present study.
Nr0b2 negatively regulates transcription of G6Pase (25) , and loss of G6Pase is commonly observed in preneoplastic foci in the rat liver (26) . Our present finding that some liver cell foci showed positive immunoreactivity of Nr0b2 as compared with surrounding liver cells in the early stage of tumor promotion might have caused decreased expression of G6Pase. In the late stage, Nr0b2 was variably expressed in the proliferative lesions without relation to lesion development. Interestingly, carcinomas showing decreased expression of Nr0b2 exhibited higher MCM6-positive cell indices in both PB-and FB-promoted livers, suggesting that the loss of Nr0b2 may be necessary for acquisition of a malignant phenotype, different from the suggested TGFb is a potent growth inhibitor in liver cells, and thus, it has been considered that down-regulation of TGFb signaling is critical for hepatocarcinogenesis (5) . There have been many studies examining expression levels of its receptors in human hepatocellular tumors, and overall, most have revealed reduction (5) . In rats, decrease of TGFbRs was reported in PB-promoted hepatocellular tumors, and it is considered that down-regulation of TGFbRs might provide a selective growth advantage to tumor cells by allowing them to escape the growth inhibitory effects of TGFb (3, 29) . Despite growth inhibitory effects of TGFb signaling on liver cells, immunoreactivity of TGFbRI and TGFbRII observed in the present study was increased or unchanged, respectively, during tumor development. Although TGFb can also act as a promoter of tumor progression during the late stage of tumorigenesis and induce tumor invasion and metastasis (30) , biological effects of increased TGFbRI expression in foci from the early stage of tumor promotion cannot be unequivocally concluded. Since MCM6-positive cell indices did not differ with the levels of TGFbRI and TGFbRII, the TGFb signaling pathway is possibly impaired in these proliferative lesions. It has been proposed that the ratio between TGFbRI and TGFbRII influences the cellular fate by controlling signaling (31) . Therefore, differences in expression patterns between TGFbRI and TGFbRII in GST-P-positive lesions might lead to dysregulation of TGFb signaling. Dysregulation of downstream effectors of TGFb, such as smad2 and smad4, has been reported to contribute to the tumor progression during chemical carcinogenesis in rats (32) . In addition, increased expression of smad7, an inhibitory downstream molecule of the TGFb signaling, has been found in many of advanced human hepatocellular carcinomas, suggestive of its role for acquisition of resistance to TGFb, especially in hepatocellular tumors without reduction of TGFbRs (33) . Thus, further investigations of factors downstream of TGFb signaling are needed to clarify the reason for the unexpected cellular distribution of TGFbRI and TGFbRII in relation to hepatocarcinogenesis.
In human hepatocellular carcinomas, it has been reported that expression of PTEN is reduced or absent in almost half of cases and reduced PTEN expression may be involved in pathogenesis and tumor progression (8, 34) . In rats, there have been only few reports of PTEN expression in the liver tumors. Silins et al. (10) described a subset of preneoplastic foci exhibiting a PTEN-positive phenotype and suggested there to be targeted for sphingolipid-induced apoptosis. In the present study, the levels of both PTEN and pPTEN were decreased consistently in the foci, adenomas and carcinomas, suggesting that reduction of PTEN function may be involved in rat hepatocarcinogenesis from an early stage. Involvement of the PI3 kinase pathway, including PTEN and AKT, has recently been shown in TGFb-induced invasion during the tumor progression process (35, 36) , implying a possible contribution to late-stage tumor promotion. Expression of the PTEN gene can be suppressed by TGFb (37) . Since increased expression of TGFbRI and decreased expression of PTEN and pPTEN were often found concomitantly in the present study, further investigation of this relationship appears warranted. Although the relation to loss of tumor suppressor function is unclear, neoplastic lesions lacking PTEN/pPTEN expression in the present study exhibited lower MCM6-positive cell indices than those retaining these antigens. Some functions related to tumor progression other than proliferation might be activated in tumors lacking PTEN/pPTEN.
In conclusion, we here found 33 genes showing altered expression specific to the early stages of tumor promotion by both FB and PB in the rat two-stage hepatocarcinogenesis model using microarray technique. Immunohistochemical analysis indicated that changes of iron 
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homeostasis following increased expression of Tfrc, specifically in proliferative lesions, contribute to tumor promotion and progression by FB or PB. Loss of Nr0b2 might possibly play a role in acquisition of the malignant phenotype in hepatocellular tumors. In addition, loss of PTEN and dysregulation of TGFb signaling may be considered to be involved in rat hepatocarcinogenesis from early stages. Thus, our approaches applied here utilizing microarray analysis and following immunohistochemical screening may help searching early biomarkers of carcinogenesis. Although further studies should address roles in the processes of hepatocarcinogenesis, obtained molecules in the present study may be beneficial for detection and evaluation of non-genotoxic carcinogens that we are at risk, as well as for understanding of the mechanism of non-genotoxic carcinogenesis to secure human health.
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